News: Sinovac's Coronavac proving safe and effective in children

Sinovac Biotech, based in China, has reported that their CoronaVac has been safe and successful at inducing an immune response in children and adolescence, following its phase I and II trials.


The trials involved over 500 participants, ages ranging from three to 17. The shots were delivered at either medium or low doses. Adverse reactions were considered mild, with only two higher fevers reported (classified as a Grade 3 adverse reaction.)


Sinovac researcher, Zeng Gang reported that the antibody levels observed after this vaccine was higher than the ones in adults aged 18 to 59. So far, Sinovac has distributed around 160 million doses of their Coronavac to 17 countries outside of China, 70 million of which have already been administered.


The lower dose seems most effective in children ages 3 to eleven, while the medium dose seems to work best for those aged 12 to 17. As most of the widely used vaccines now do not target children, the news is promising for future development.


Other trials are also currently underway to test out the Pfizer, Moderna, and AstraZeneca vaccines on older children, particularly those with chronic illnesses that may leave them more vulnerable to the effects of the virus.


American director of the National Institute of Allergy and Infectious diseases, Doctor Anothony Fauci, has said that high school students should be able to receive their vaccine in the Autumn.


Stay up to date on Clinical Studies


Citrus is a fully integrated recruitment and retention software that fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.

Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.

Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.

With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.


Check out what our customers have to say about us here.

And If you’d like to know more about how Citruslabs can help you recruit more effectively, get in touch with our team here.